Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SXRN Injection in Cancer Cachexia
NCT07890324Phase 2Not yet recruiting
- Sponsor
- Jiangsu Guiqiong Pharmaceutical
- Start
- Dec 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 2 trial of SXRN in cancer anorexia-cachexia syndrome (CACS), sponsored by Jiangsu Guiqiong Pharmaceutical. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
SXRN
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on NCT07890324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07890324.